Using dissolution and pharmacokinetics studies of crystal form to optimize the original iloperidone

Crystal Growth and Design

Volumn 13, Issue 12, 2013, Pages 5261-5266

  Zhang, Tingting ^a   Yang, Yan ^b   Wang, Haitao ^a   Sun, Fuxing ^b   Zhao, Xiaojun ^b   Jia, Jiangtiao ^b   Liu, Jingrui ^b   Guo, Wei ^b   Cui, Xiaoqiang ^a   Gu, Jingkai ^b   Zhu, Guangshan ^b  

^a Jilin University   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 ,3-DIHYDROXYBENZOIC ACID (2 ,3-DHBA); 3 ,5-DIHYDROXYBENZOIC ACID; 3-HYDROXYBENZOIC ACIDS; ACTIVE PHARMACEUTICAL INGREDIENTS; DISSOLUTION BEHAVIOR; PHARMACOKINETIC PROFILES; REACTION CRYSTALLIZATION; SUPRAMOLECULAR SYNTHESIS;

DRUG PRODUCTS; PHARMACOKINETICS;

DISSOLUTION;

EID: 84889857630     PISSN: 15287483     EISSN: 15287505     Source Type: Journal    
DOI: 10.1021/cg4010104     Document Type: Article

References (28)

1. Soldatov, D. V.; Terekhova, I. S. J. Struct. Chem. 2005, 46, S1-S8
2. Desiraju, G. R. Angew. Chem., Int. Ed. 2007, 46, 8342-8356
3. Reddy, L. S.; Babu, N. J.; Nangia, A. Chem. Commun. 2006, 13, 1369-1371
4. Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J. J. Pharm. Sci. 2006, 95, 499-516
5. Shan, N.; Zaworotko, M. J. Drug Discovery Today 2008, 13, 440-446
6. Schultheiss, N.; Bethune, S.; Henck, J. O. CrysteEngComm 2010, 12, 2436-2442
7. Cheney, M. L.; Shan, N.; Healey, E. R.; Hanna, M.; Wojtas, L.; Zaworotko, M. J.; Sava, V.; Song, S. J.; Sanchez-Ramos, J. R. Cryst. Growth Des. 2010, 10, 394-405
8. Bak, A.; Gore, A.; Yanez, E.; Stanton, M.; Tufekcic, S.; Syed, R.; Akrami, A.; Rose, M.; Surapaneni, S.; Bostick, T.; King, A.; Neervannan, S.; Ostovic, D.; Koparkar, A. J. Pharm. Sci. 2008, 97, 3942-3956
9. Stanton, M. K.; Bak, A. Cryst. Growth Des. 2008, 8, 3856-3862
10. Thakur, T. S.; Desiraju, G. R. Cryst. Growth Des. 2008, 8, 4031-4044
11. Kavuru, P.; Aboarayes, D.; Arora, K. K.; Clarke, H. D.; Kennedy, A.; Marshall, L.; Ong, T. T.; Perman, J.; Pujari, T.; Wojtas, L.; Zaworotko, M. J. Cryst. Growth Des. 2010, 10, 3568-3584
12. Fang, Q. R.; Zhu, G. S.; Xue, M.; Wang, Z. P.; Sun, J. Y.; Qiu, S. L. Cryst. Growth Des. 2008, 8, 319-329
13. Xue, M.; Zhu, G. S.; Li, Y. X.; Zhao, X. J.; Jin, Z.; Kang, E.; Qiu, S. L. Cryst. Growth Des. 2008, 8, 2478-2483
14. Jia, J. T.; Sun, F. X.; Fang, Q. R.; Liang, X. Q.; Cai, K.; Bian, Z.; Zhao, H. J.; Gao, L. X.; Zhu, G. S. Chem. Commun. 2011, 47, 9167-9169
15. Han, L. Q.; Yan, Y.; Sun, F. X.; Cai, K.; Borjigin, T.; Zhao, X. J.; Qu, F. Y.; Zhu, G. S. Cryst. Growth Des. 2013, 13, 1458-1463
16. Citrome, L. Expert Opin. Drug Metab. Toxicol. 2010, 6, 1551-1564
17. Arif, S. A.; Mitchell, M. M. Am. J. Health-Syst. Pharm. 2011, 68, 301-308
18. Citrome, L. Int. J. Clin. Pract. 2009, 63, 1237-1248
19. Corbett, R.; Griffiths, L.; Shipley, J. E.; Shukla, U.; Strupczewski, J. T.; Szczepanik, A. M.; Szewczak, M. R.; Turk, D. J.; Vargas, H. M.; Kongsamut, S.; Team, t. I. P. CNS Drug Rev. 1997, 3, 120-147
20. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. Pharm. Res. 1995, 12, 413-420
21. Chemistry reviews. Centre for drug evaluation and research. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022192s000-ChemR.pdf (accessed January 9, 2009).
22. Wu, C. Y.; Benet, L. Z. Pharm. Res. 2005, 22, 11-23
23. Caccia, S.; Pasina, L.; Nobili, A. Drug Des., Dev. Ther. 2010, 4, 33-48
24. Reddy, L. S.; Bethune, S. J.; Kampf, J. W.; Rodriguez-Hornedo, N. Cryst. Growth Des. 2009, 9, 378-385
25. VenkateSh, G.; Lai, J. W.; Vyas, N. H.; Purohit, V. Drug delivery systems comprising weakly basic drugs and organic acids. U.S. Patent 8,133,506 B2, March 13, 2012.
26. Polentarutti, B.; Albery, T.; Dressman, J.; Abrahamsson, B. J. Pharm Pharmacol. 2010, 62, 462-469
27. Preskorn, S. H. J. Psychiatr. Pract. 2012, 18, 199-204
28. Preskorn, S. H. J. Psychiatr. Pract. 2012, 18, 361-368